MedTrace Logo

Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies

NCT01529437 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2015-11-26

No results posted yet for this study

Summary

This is a study for children and adults who are interested in a new therapy for their allergies to dust mite and timothy grass. The new therapy is called sublingual immunotherapy and the investigators are testing if it is safe and well tolerated.

Conditions

Interventions

DRUG

sublingual immunotherapy

Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.

DRUG

placebo sublingual immunotherapy

SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding

Sponsors & Collaborators

Principal Investigators

  • Kari Nadeau, MD, PhD · Stanford University Faculty

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01529437 on ClinicalTrials.gov